PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule

Radiotherapy and Oncology

Volumn 110, Issue 2, 2014, Pages 355-361

  Lund Andersen, Christin ^a   Patzke, Sebastian ^a   Nähse Kumpf, Viola ^a   Syljuåsen, Randi G ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cancer; Combined treatment; DNA damage; G2 checkpoint; Ionizing radiation; Mitosis; PLK1 inhibitors

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; DNA; POLO LIKE KINASE 1; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

ARTICLE; BIOACCUMULATION; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL KILLING; CELL STRAIN HT29; CELL SURVIVAL; CLONOGENIC ASSAY; COLORECTAL CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG CYTOTOXICITY; ENZYME INHIBITION; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOSIS; OSTEOSARCOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; TIME LAPSE IMAGING; TIME TO TREATMENT; X IRRADIATION; X RAY GENERATOR; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CELL CYCLE; CHEMORADIOTHERAPY; COLONIC NEOPLASMS; DRUG EFFECTS; GENETICS; HT 29 CELL LINE; PATHOLOGY; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL LINE;

BONE NEOPLASMS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CHEMORADIOTHERAPY; COLONIC NEOPLASMS; DNA DAMAGE; DNA REPAIR; FLOW CYTOMETRY; HT29 CELLS; HUMANS; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RADIATION TOLERANCE;

EID: 84896400978     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2013.12.014     Document Type: Article

References (40)

1. Y. Degenhardt, and T. Lampkin Targeting Polo-like kinase in cancer therapy Clin Cancer Res 16 2010 384 389
2. K. Strebhardt, and A. Ullrich Targeting polo-like kinase 1 for cancer therapy Nat Rev 6 2006 321 330
3. M.A. van Vugt, A. Bras, and R.H. Medema Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells Mol Cell 15 2004 799 811 (Pubitemid 39194909)
4. M.A. van Vugt, and R.H. Medema Getting in and out of mitosis with Polo-like kinase-1 Oncogene 24 2005 2844 2859 (Pubitemid 40638094)
5. T. Menzel, V. Nähse-Kumpf, and A.N. Kousholt et al. A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance EMBO Rep 12 2011 705 712
6. R.G. Syljuåsen, S. Jensen, J. Bartek, and J. Lukas Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases Cancer Res 66 2006 10253 10257 (Pubitemid 44799740)
7. L. Macurek, A. Lindqvist, and D. Lim et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery Nature 455 2008 119 123
8. D. Deckbar, J. Birraux, and A. Krempler et al. Chromosome breakage after G2 checkpoint release J Cell Biol 176 2007 749 755 (Pubitemid 46425534)
9. M. Löbrich, and P.A. Jeggo The impact of a negligent G2/M checkpoint on genomic instability and cancer induction Nat Rev 7 2007 861 869 (Pubitemid 350006255)
10. R.G. Syljuåsen Checkpoint adaptation in human cells Oncogene 26 2007 5833 5839
11. K. Tkacz-Stachowska, C. Lund-Andersen, A. Velissarou, J.H. Myklebust, T. Stokke, and R.G. Syljuåsen The amount of DNA damage needed to activate the radiation-induced G2 checkpoint varies between single cells Radiother Oncol 101 2011 24 27
12. D.C. Christoph, and M. Schuler Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies Expert Rev Anticancer Ther 11 2011 1115 1130
13. T. Takahashi, B. Sano, and T. Nagata et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers Cancer Sci 94 2003 148 152 (Pubitemid 36575873)
14. S. Ackermann, F. Goeser, and J.H. Schulte et al. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma Clin Cancer Res 17 2011 731 741
15. Y.B. Feng, D.C. Lin, and Z.Z. Shi et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of surviving level in esophageal squamous cell carcinoma Int J Cancer 124 2009 578 588
16. B. Spankuch-Schmitt, G. Wolf, and C. Solbach et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells Oncogene 21 2002 3162 3171 (Pubitemid 34548087)
17. S. Yamada, M. Ohira, and H. Horie et al. Expression profiling and differential screening between hepatoblastomas and the corresponding normal livers: identification of high expression of the PLK1 oncogene as a poor-prognostic indicator of hepatoblastomas Oncogene 23 2004 5901 5911 (Pubitemid 39093534)
18. A. Frost, K. Mross, and S. Steinbild et al. Phase I study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours Curr Oncol (Toronto Ont) 19 2012 e28 e35
19. R.H. Medema, C.C. Lin, and J.C. Yang Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC Clin Cancer Res 17 2012 6459 6466
20. K. Strebhardt Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat Rev Drug Discov 9 2010 643 660
21. P. Lenart, M. Petronczki, and M. Steegmaier et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr Biol 17 2007 304 315
22. M. Steegmaier, M. Hoffmann, and A. Baum et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr Biol 17 2007 316 322 (Pubitemid 46241881)
23. J. Luo, M.J. Emanuele, and D. Li et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene Cell 137 2009 835 848
24. Y. Yamamoto, H. Matsuyama, and S. Kawauchi et al. Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer Oncology 70 2006 231 237 (Pubitemid 44154697)
25. X. Liu, M. Lei, and R.L. Erikson Normal cells, but not cancer cells, survive severe Plk1 depletion Mol Cell Biol 26 2006 2093 2108 (Pubitemid 43346913)
26. M. Raab, S. Kappel, and A. Kramer et al. Toxicity modelling of Plk1-targeted therapies in genetically engineered mice and cultured primary mammalian cells Nat Commun 2 2011 395
27. K. Gerster, W. Shi, and B. Ng et al. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma Int J Radiat Oncol Biol Phys 77 2010 253 260
28. P.S. Harris, S. Venkataraman, and I. Alimova et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells BMC Cancer 12 2012 80
29. F. Rodel, S. Keppner, and G. Capalbo et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer Am J Pathol 177 2010 918 929
30. G.I. Terzoudi, K.N. Manola, G.E. Pantelias, and G. Iliakis Checkpoint abrogation in G2 compromises repair of chromosomal breaks in ataxia telangiectasia cells Cancer Res 65 2005 11292 11296 (Pubitemid 41821685)
31. E. Hall, and A. Giaccia Radiobiology for the radiologist 6th ed. 2006 Lippincott Williams & Wilkin Philadelphia, USA
32. B. Pauwels, A. Wouters, M. Peeters, J.B. Vermorken, and F. Lardon Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation Future Oncol 6 2010 1485 1496
33. S. Bekker-Jensen, C. Lukas, F. Melander, J. Bartek, and J. Lukas Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1/NFBD1 J Cell Biol 170 2005 201 211 (Pubitemid 41043803)
34. J. Haupenthal, V. Bihrer, and H. Korkusuz et al. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels Neoplasia 14 2012 410 419
35. M.J. Hendzel, Y. Wei, and M.A. Mancini et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation Chromosoma 106 1997 348 360 (Pubitemid 27510848)
36. G. Nelson, M. Buhmann, and T. von Zglinicki DNA damage foci in mitosis are devoid of 53BP1 Cell Cycle 8 2009 3379 3383
37. W.B. Dalton, M.O. Nandan, R.T. Moore, and V.W. Yang Human cancer cells commonly acquire DNA damage during mitotic arrest Cancer Res 67 2007 11487 11492
38. M. Sui, H. Zhang, X. Di, J. Chang, Y. Shen, and W. Fan G2 checkpoint abrogator abates the antagonistic interaction between antimicrotubule drugs and radiation therapy Radiother Oncol 104 2012 243 248
39. N. Somaiah, J. Yarnold, A. Lagerqvist, K. Rothkamm, and T. Helleday Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy Radiother Oncol 108 2013 155 161
40. M. Krause, B. Kummer, and A. Deparade et al. Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation Radiother Oncol 108 2013 422 428